Hu Joyce K, Crampton Jordan C, Cupo Albert, Ketas Thomas, van Gils Marit J, Sliepen Kwinten, de Taeye Steven W, Sok Devin, Ozorowski Gabriel, Deresa Isaiah, Stanfield Robyn, Ward Andrew B, Burton Dennis R, Klasse Per Johan, Sanders Rogier W, Moore John P, Crotty Shane
Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA Center for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, California, USA.
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
J Virol. 2015 Oct;89(20):10383-98. doi: 10.1128/JVI.01653-15. Epub 2015 Aug 5.
Generating neutralizing antibodies (nAbs) is a major goal of many current HIV-1 vaccine efforts. To be of practical value, these nAbs must be both potent and cross-reactive in order to be capable of preventing the transmission of the highly diverse and generally neutralization resistant (Tier-2) HIV-1 strains that are in circulation. The HIV-1 envelope glycoprotein (Env) spike is the only target for nAbs. To explore whether Tier-2 nAbs can be induced by Env proteins, we immunized conventional mice with soluble BG505 SOSIP.664 trimers that mimic the native Env spike. Here, we report that it is extremely difficult for murine B cells to recognize the Env epitopes necessary for inducing Tier-2 nAbs. Thus, while trimer-immunized mice raised Env-binding IgG Abs and had high-quality T follicular helper (Tfh) cell and germinal center (GC) responses, they did not make BG505.T332N nAbs. Epitope mapping studies showed that Ab responses in mice were specific to areas near the base of the soluble trimer. These areas are not well shielded by glycans and likely are occluded on virions, which is consistent with the lack of BG505.T332N nAbs. These data inform immunogen design and suggest that it is useful to obscure nonneutralizing epitopes presented on the base of soluble Env trimers and that the glycan shield of well-formed HIV Env trimers is virtually impenetrable for murine B cell receptors (BCRs).
Human HIV vaccine efficacy trials have not generated meaningful neutralizing antibodies to circulating HIV strains. One possible hindrance has been the lack of immunogens that properly mimic the native conformation of the HIV envelope trimer protein. Here, we tested the first generation of soluble, native-like envelope trimer immunogens in a conventional mouse model. We attempted to generate neutralizing antibodies to neutralization-resistant circulating HIV strains. Various vaccine strategies failed to induce neutralizing antibodies to a neutralization-resistant HIV strain. Further analysis revealed that mouse antibodies targeted areas near the bottom of the soluble envelope trimers. These areas are not easily accessible on the HIV virion due to occlusion by the viral membrane and may have resulted from an absence of glycan shielding. Our results suggest that obscuring the bottom of soluble envelope trimers is a useful strategy to reduce antibody responses to epitopes that are not useful for virus neutralization.
产生中和抗体(nAbs)是当前许多HIV-1疫苗研发工作的主要目标。为具有实际应用价值,这些中和抗体必须既高效又具有交叉反应性,以便能够预防正在传播的高度多样化且通常具有中和抗性(2级)的HIV-1毒株的传播。HIV-1包膜糖蛋白(Env)刺突是中和抗体的唯一靶点。为探究Env蛋白是否能诱导产生2级中和抗体,我们用模拟天然Env刺突的可溶性BG505 SOSIP.664三聚体免疫常规小鼠。在此,我们报告,鼠B细胞极难识别诱导2级中和抗体所需的Env表位。因此,虽然用三聚体免疫的小鼠产生了Env结合IgG抗体,并具有高质量的滤泡辅助性T(Tfh)细胞和生发中心(GC)反应,但它们并未产生BG505.T332N中和抗体。表位作图研究表明,小鼠中的抗体反应针对可溶性三聚体底部附近的区域。这些区域未被聚糖很好地屏蔽,且在病毒粒子上可能被遮挡,这与缺乏BG505.T332N中和抗体一致。这些数据为免疫原设计提供了信息,并表明掩盖可溶性Env三聚体底部呈现的非中和表位是有用的,且结构良好的HIV Env三聚体的聚糖屏蔽对鼠B细胞受体(BCR)实际上是不可穿透的。
人类HIV疫苗效力试验尚未产生针对循环HIV毒株的有意义的中和抗体。一个可能的障碍是缺乏能正确模拟HIV包膜三聚体蛋白天然构象的免疫原。在此,我们在常规小鼠模型中测试了第一代可溶性、类似天然的包膜三聚体免疫原。我们试图产生针对具有中和抗性的循环HIV毒株的中和抗体。各种疫苗策略均未能诱导产生针对具有中和抗性的HIV毒株的中和抗体。进一步分析表明,小鼠抗体靶向可溶性包膜三聚体底部附近的区域。由于被病毒膜遮挡,这些区域在HIV病毒粒子上不易接近,且可能是由于缺乏聚糖屏蔽所致。我们的结果表明,掩盖可溶性包膜三聚体的底部是一种有用的策略,可减少对病毒中和无用的表位的抗体反应。